CLINICAL AND GENETIC FEATURES OF THE COURSE OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AGAINST THE BACKGROUND OF CARDIOVASCULAR DISEASES WHO UNDERWENT COVID -19
Main Article Content
Abstract
During the COVID-19 pandemic, many large studies have confirmed a direct relationship between the severity of an infectious disease and a history of diabetes mellitus. Diabetes, hypertension, and especially cardiovascular disease are important risk factors for the severity and mortality of people infected with COVID-19. The severe course of covid-19 in patients with diabetes mellitus on the background of cardiovascular pathology is associated with the development of endothelial dysfunction, which served to start our own research in this direction and to establish a connection between the course of type 2 diabetes mellitus and the role of the C3872T polymorphism of the CRP gene in this pathological process .
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Angelidi A.M., Belanger M.J., Mantzoros C.S. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metabolism 2020; 107: 154245, https://doi.org/10.1016/j
Abou-Ismail M.Y., Diamond A., Kapoor S., Arafah Y., Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res 2020; 194: 101–115, https://doi.org/10.1016/j.thromres.2020.06.029.
Yang J.K., Lin S.S., Ji X.J., Guo L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010; 47(3): 193–199,https://doi.org/10.1007/s00592-009-0109-44.
Center for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). U.S. Department of Health & Human Services; 2020. URL: https://www.cdc.gov/ coronavirus/2019-ncov/hcp/clinical-guidance-managementpatients.html.
CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 382–386, https://doi.org/10.15585/mmwr.mm6913e2.
Deng S.Q., Peng H.J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 2020; 9(2): 575, https://doi.org/10.3390/jcm9020575. 7. Diaz J.H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Trav Med 2020; 27(3):taaa041,https://doi.org/10.1093/jtm/taaa041.
Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020; 43(6):867–869,https://doi.org/10.1007/s40618-020-01236-2.
Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M., Liu X.Q., Chen R.C., Tang C.L., Wang T., Ou C.Q., Li L., Chen P.Y., Sang L., Wang W., Li J.F., Li C.C., Ou L.M., China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55(5): 2000547, https://doi.org/10.1183/13993003.00547-2020.
Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., Cereda D., Coluccello A., Foti G., Fumagalli R., Iotti G., Latronico N., Lorini L., Merler S., Natalini G., Piatti A., Ranieri M.V., Scandroglio A.M., Storti E., Cecconi M., Pesenti A.; COVID-19 Lombardy ICU Network; Nailescu A., Corona A., Zangrillo A., Protti A., Albertin A., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323(16): 1574–1581, https://doi.org/10.1001/ jama.2020.5394.
Liu W., Li H. COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv 2020; https://doi.org/10.26434/chemrxiv.11938173.v7.
. Maffetone P.B., Laursen P.B. The perfect storm: coronavirus (COVID-19) pandemic meets overfat pandemic. Front Public Health 2020; 8: 135, https://doi.org/10.3389/ fpubh.2020.00135.
31. Muniyappa R., Gubbi S. The COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020; 318(5): E736–E741, https://doi.org/10.1152/ajpendo.00124.2020.
Maddaloni E., Buzzetti R. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev 2020; e33213321 , https://doi.org/10.1002/dmrr.3321 . [ PMC free article ] [ PubMed ]
Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; https://doi.org/10.1001/population.2020.4683. [ PMC free article ] [ PubMed ]
Puig -Domingo M, Marazuela M, Giustina A. COPD and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 2020 ;68 (1):2–5; [ PMC free article ] [ PubMed ]
Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci2017 ;18 (3):563; [ PMC free article ] [ PubMed ]
Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, Deftereos S, Tousoulis D. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 2019; 14(1): 50– 59, https://doi.org/10.15420/ecr.2018.33.1. [ PMC free article ] [ PubMed ]
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395(10234):1417–1418, https://doi.org/10.1016/S0140-6736(20)30937-5.25.Diaz JH